Designed a biologically engineered solution to combat anti-biotic resistant cholera
We stole the targeting mechanism from naturally occurring bacteriophages (a type of virus) to specifically target cholera bacteria. We attached the targeting mechanism onto B. bacteriovorus, a bacterium that eats other gram-negative bacteria, thereby creating a naturally occurring anti-bacterial therapeutic.
Designed a biologically engineered therapy to combat Clostridium difficile Associated Diseases (CDAD)
Genetically modified the genes of probiotic bacteria to produce and export proteases (enzymes that digest proteins) for release within the body, as a step in the therapy to treat CDAD.
Supported the development of a new digital classifications schema for the detection of cancer treatment variances
As the Director of Client Services and Operations at Cota, I played an integral role in collecting real world data and analyzing it to develop a new digital classification schema for variance detection in treatments and outcomes for cancer. Cota's work was published as a part of the American Society of Clinical Oncology's annual conference.